Stage IV (D)/Relapsed Colon Cancer

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer (11-3-2014)

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal cancer. According... Continue Reading

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (10-23-2014)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society,... Continue Reading

Doctors find that Cholesterol Lowering Statin Drugs may Improve Survival From Colon Cancer (08-26-2014)

According to a new U.K. study, statins, which are widely used cholesterol-lowering drugs, appear to improve colon cancer survival.  The study found that overall, colon cancer patients who took statins such as Lipitor and Zocor had a 29 percent lower... Continue Reading

TAS-102 Improves Survival in Advanced Colorectal Cancer (07-9-2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (06-20-2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (03-5-2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (02-7-2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Erbitux Plus FOLFIRI Outperforms Avastin Plus FOLFIRI for First-Line Treatment of Metastatic Colorectal Cancer (06-20-2013)

For the initial (first-line) treatment of metastatic colorectal cancer with no KRAS gene mutations, the combination of Erbitux® (cetuximab) and FOLFIRI chemotherapy was more effective than the combination of Avastin® (bevacizumab) and FOLFIRI. These... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (05-29-2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Combo Treatment Effective in Elderly Patients with Metastatic Colorectal Cancer (03-6-2013)

Combination therapy with Avastin® (bevacizumab) and Xeloda® (capecitabine) may be an optimal first-line treatment for treatment-naïve older patients with metastatic colorectal cancer, according to the results of a study presented at the 2013 Gastrointestinal... Continue Reading

« Previous PageNext Page »